Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Peripheral Neuropathy Treatment Market, by Type, by Treatment (Pharmacological Therapies and Non-pharmacological Therapies, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published by Coherent Market Insights Product code 980048
Published Content info 205 Pages
Delivery time: 2-3 business days
Price
Back to Top
Peripheral Neuropathy Treatment Market, by Type, by Treatment (Pharmacological Therapies and Non-pharmacological Therapies, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Published: December 31, 2020 Content info: 205 Pages
Description

Title:
Peripheral Neuropathy Treatment Market, by Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), by Treatment (Pharmacological Therapies (Pain Relievers, Anti-seizure Medications, and Antidepressants) and Non-pharmacological Therapies (Transcutaneous Electrical Nerve Stimulation, Plasma Exchange and Intravenous Immune Globulin, and Others), by Distribution Channel (Hospitals and Clinics, Ambulatory Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Peripheral neuropathy is a disorder that affects the peripheral nerves. Peripheral neuropathy has a variety of systemic, metabolic, and toxic causes, for instance diabetes in metabolic cause. The most common treatable causes include diabetes mellitus, hypothyroidism, and nutritional deficiencies. The diagnosis require careful clinical assessment, judicious laboratory testing, and electro diagnostic studies or nerve biopsy, if the diagnosis remains unclear.

Market Dynamics

Rising aging population is expected to drive the global peripheral neuropathy treatment market growth. For instance, according to an article published by the World Health Organization (WHO) in February 2018, reports that between 2015 and 2050, the proportion of the worldwide geriatric population will nearly double from 12% to 22%.

Moreover, rising diabetic cases is expected to drive the market growth. For instance, according to an article published by the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

researched

medicinal properties of cannabis and its derivatives are widely

Researched

Medicinal properties of cannabis and its derivatives are widely

researched

medicinal properties of cannabis and its derivatives are widely

researched

medicinal properties of cannabis and its derivatives are widely

researched

Key features of the study:

  • This report provides in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd, among others.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

  • Global Peripheral Neuropathy Treatment Market, By Type:
    • Diabetic Peripheral Neuropathy
    • Chemotherapy-induced Peripheral Neuropathy
    • Idiopathic Peripheral Neuropathy
    • Others
  • Global Peripheral Neuropathy Treatment Market, By Treatment:
    • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
    • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
  • Global Peripheral Neuropathy Treatment Market, By Distribution Channel:
    • Hospitals and Clinics
    • Ambulatory Centers
    • Others
  • Global Peripheral Neuropathy Treatment Market, By Region:
    • North America
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Type:
      • Diabetic Peripheral Neuropathy
      • Chemotherapy-induced Peripheral Neuropathy
      • Idiopathic Peripheral Neuropathy
      • Others
      • By Treatment:
      • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
      • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
      • By Distribution Channel:
      • Hospitals and Clinics
      • Ambulatory Centers
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Abbott*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol Myers Squibb
    • Cipla Limited
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Lupin Limited
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Dr. Reddy's Laboratories
    • Mylan NV
    • Johnson & Johnson Services Inc.
    • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Treatment
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Peripheral Neuropathy Treatment Products

5. Global Peripheral Neuropathy Treatment Market, By Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Diabetic Peripheral Neuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Chemotherapy-induced Peripheral Neuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Idiopathic Peripheral Neuropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Pharmacological Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Pain Relievers
    • Anti-seizure Medications
    • Antidepressants
  • Non-pharmacological Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Transcutaneous Electrical Nerve Stimulation
    • Plasma Exchange and Intravenous Immune Globulin
    • Others

7. Global Peripheral Neuropathy Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Ambulatory Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

8. Global Peripheral Neuropathy Treatment Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Abbott
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cipla Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Lupin Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck and Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan NV
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson Services Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies

10. Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top